Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome -- A Prospective, Randomized, Controlled Clinical Trial
Overview
- Phase
- Phase 2
- Intervention
- bromocriptine
- Conditions
- Ovarian Hyperstimulation Syndrome
- Sponsor
- Sun Yat-sen University
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Incidence of moderate and severe OHSS
- Last Updated
- 9 years ago
Overview
Brief Summary
This prospective, randomized, controlled clinical trial will evaluate the effect and security of dexamethasone prevention for Patients of Ovarian Hyperstimulation Syndrome.
Detailed Description
Ovarian hyperstimulation syndrome (OHSS) is a iatrogenic complication of ovarian stimulation,which in its severe form is associated with significant morbidity and can be life threatening. It is characterized by cystic enlargement of the ovaries and rapid fluid shifts from the intravascular compartment to the third space. It is thought that increased vascular permeability is the pivotal mechanism of OHSS pathophysiology. The administration of human chorionic gonadotrophin results in the release of vasoactive substance such as vascular endothelial growth factor that causes vasodilation and leakage of fluids. Glucocorticoids and their synthetic derivatives have an inhibitory effect on the VEGF gene expression in vascular smooth muscle cells. By reducing leukocytic infiltration and the release of inflammatory mediator, inhibiting vasodilation and preventing increases in vascular permeability, these agents can dampen the inflammatory response and prevent edema formation ,thus offering a potential therapeutic intervention for OHSS. Investigators have observed more than a hundred patients in clinical practice that low-dose dexamethasone has prevention action for patients in IVF cycles at high risk of OHSS. This clinical trial is designed to evaluate the effect and security of dexamethasone prevention for patients of Ovarian Hyperstimulation Syndrome. There are two groups: bromocriptine group, dexamethasone group .After followed-up for 7 days , Clinical OHSS parameters will be collected at oocyte retrieval and at the 4rd d and 6th d of treatment .
Investigators
Yanhong Deng
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Women of reproductive age
- •Women having controlled ovarian hyperstimulation as part of any assisted reproductive technique
- •Women at risk of severe OHSS(serum estradiol levels were\>3000pg/ml on the day of HCG trigger ; there was retrieval of 20 or more oocytes)
Exclusion Criteria
- •Unwillingness to comply with the study protocol.
- •Attending other clinical trials in the same period.
- •Chronic glucocorticoid their synthetic derivatives intake.
- •History of allergic to study medications.
- •The patients who cannot take dexamethasone.： hypertension, diabetes,gastric ulcer; abnormal renal or hepatic function and so on.
Arms & Interventions
bromocriptine group
Rectal bromocriptine (2.5 mg, qd) for 7 days
Intervention: bromocriptine
dexamethasone group
Oral take dexamethasone(3mg,qd)for 7 days
Intervention: dexamethasone
Outcomes
Primary Outcomes
Incidence of moderate and severe OHSS
Time Frame: 7 days
Moderate OHSS is characterized by the presence of ascites on ultrasound examination ,moderate hemoconcentration and elevated leukocytes.Symptoms include abdominal distension , nausea and vomiting . And diagnosis of severe OHSS required clinical evidence of ascites or hydrothorax or breathing difficulties or one of the following criteria: 1) increased blood viscosity i.e. hemoglobin at least 15 gm%, hematocrit at least 45%, or leucocyte count at least 20,000 per cubic millimeter. 2) coagulation abnormality.3) liver dysfunction, defined when transaminases (AST or ALT) are more than 40 u/ml.
Secondary Outcomes
- Adverse side effects of treatment(7 days)